INNOVIVA,INC. (NASDAQ:INVA) Files An 8-K Other Events
Item 8.01. Other Events.
On April10, 2017,Innoviva,Inc. announced that it planned to
prepay $50 million in outstanding principal on its non-recourse
royalty notes due 2029 as part of its previously announced $150
million capital return program for 2017. The press release is
filed as Exhibit99.1 to this report and is incorporated herein by
Item9.01. Financial Statements and Exhibits.
Press Release dated April10, 2017
About INNOVIVA, INC. (NASDAQ:INVA)
Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA. INNOVIVA, INC. (NASDAQ:INVA) Recent Trading Information
INNOVIVA, INC. (NASDAQ:INVA) closed its last trading session up +0.60 at 14.22 with 9,868,603 shares trading hands.